From Leveraging Emerging Predictive Technologies to Engineering a Human-Physiologically Relevant Models – Deepen Our Understanding of Tumor Biology, Resistance Mechanisms & Dosing Strategy Following the success of KRAS, HER2, BCMA, drug developers have seen a new wave of novel, combination targeted oncology surging through pipeline.
12-14 July 2022